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The tumor suppressor p53 is one of 
the key sentinels in the cell for moni-
toring the integrity of genomic DNA. 
When deleterious mutations occur, 
p53 launches a DNA repair pathway 
and arrests the cell cycle to protect 
daughter cells from inheriting poten-
tially mutagenic DNA (Vousden and 
Prives, 2009). Exquisitely sensitive to 
DNA damage, p53 can respond to even 
one or two breaks in nuclear DNA, but 
it apparently ignores harmless breaks 
that naturally form as DNA is opened 
during the replication phase of the cell 
cycle. Thus, a central question has 
been how p53 maintains its high sen-
sitivity to mutagenic damage while 
simultaneously overlooking benign 
breaks during normal cell division. In 
this issue of Cell, Loewer et al. (2010) 
use an elegant single-cell microscopy 
approach to address this fundamen-
tal question. They find that the activity 
of p53 is surprisingly uncoupled from 
its cellular concentration; instead, its 
activity depends on the interplay of 
inhibitory and activating posttransla-
tional modifications.
The classical model for activation of 
p53 is based primarily on experiments 
with large cell populations. These stud-
ies concluded that the levels of p53 
protein in the cell are kept low under 
normal cell-cycle conditions. DNA dam-
age triggers an initial boost in p53 con-
centration in the cell by activating the 
p53 promoter and stabilizing existing 
p53 protein (Kruse and Gu, 2009). If the 
DNA damage persists, p53 then can 
kick off a cell-cycle arrest response in 
part by stimulating gene expression of 
specific targets, including p21. Eventu-
ally, the activity of p53 is attenuated as 
it switches on another key target gene, 
mdm2. The Mdm2 protein represses 
transcriptional activation of p53 while 
simultaneously lowering p53 protein lev-
els through ubiquitin-mediated degrada-
tion (Vousden and Prives, 2009; Kruse 
and Gu, 2009).
In their new study, Loewer et al. (2010) 
now uncover a new twist in the mecha-
nism of p53 activation. By examining 
individual cells with time-lapse micros-
copy, they find that the levels of p53 
protein actually pulse up and down dur-
ing the normal cell cycle. Furthermore, 
the bursts in p53 concentration require 
kinases, such as the ataxia telangiecta-
sia mutated (ATM) kinase, which phos-
phorylates and stabilizes p53 (Vousden 
and Prives, 2009; Kruse and Gu 2009). 
These oscillations in p53 during nor-
mal growth were not detected by ear-
lier studies because they average out 
over a population of cells. Interestingly, 
Loewer et al. find that these “normal” 
pulses, which are probably triggered by 
transient DNA damage during DNA rep-
lication, do not lead to activation of p21 
or cell-cycle arrest. In contrast, bursts 
of p53 triggered by extrinsic mutagens, 
such as radiation and drugs, do activate 
p21 and halt cell division. Remarkably, 
the intensity and duration of these p53 
pulses were similar under both condi-
tions. How then does p53 differentiate 
between benign breaks in DNA and 
potentially dangerous ones?
Loewer and colleagues find that the 
critical signal controlling the activity of 
p53 is an intricate balance of alterna-
tive posttranslational modifications of 
p53. Recent studies have found that, 
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How do regulatory switches achieve high sensitivity within the noisy cellular milieu? Loewer et al. 
(2010) now use single-cell microscopy to demonstrate that alternative posttranslational modifica-
tions allow the tumor suppressor p53 to differentiate between benign breaks in DNA during the cell 
cycle and deleterious damage caused by mutagens.
like histone proteins, p53 is the target 
of myriad posttranslational modifica-
tions at numerous lysine (K) residues, 
primarily at its carboxyl terminus region 
(Figure 1) (Vousden and Prives, 2009; 
Kruse and Gu 2009). As with many his-
tone proteins, acetylation activates p53, 
whereas methylation can either activate 
(at K372) or repress (at K370, K373, and 
K382) this transcription factor (Huang 
and Berger, 2008; Huang et al., 2010). 
Interestingly, several of these alterna-
tive modifications occur on the same or 
adjacent lysine residues in the carboxyl 
terminus (Figure 1). In addition, these 
lysines can also be ubiquitinated to tar-
get p53 for degradation.
The importance and significance 
of these lysine modifications in p53’s 
carboxyl terminus have been contro-
versial. Several studies with transgenic 
mice found that mutating a subset of 
these lysines had only modest effects 
on the activity of p53 (Toledo and Wahl, 
2006). In contrast, a subsequent study 
in cell culture found that p53 function 
was dramatically reduced when all 
acetylated sites were mutated (Tang et 
al., 2008). However, studies with mice 
engineered to express this acetylation-
deficient form of p53 have not been 
reported yet.
Adding to the complexity of the story, 
lysine methylation, which occurs at 
many of the same residues as acetyla-
tion (Figure 1), appears to repress p53 
activity (Vousden and Prives, 2009; 
Huang and Berger, 2008). This is con-
fusing because the context of repres-
sion has not been clear; does methyla-
tion maintain low basal activity of p53 
during the normal cell cycle, or does 
it attenuate the activity of p53 after a 
stress response? One potential expla-
nation for the conflicting results of the 
functional studies is that these lysines 
may be alternatively acetylated for acti-
vation, methylated for repression, and 
ubiquitinated for degradation. Thus, 
the opposing actions of these modifica-
tions may mask the effects of removing 
the lysine residues from p53. In other 
words, substitution of the lysines with 
other residues leads to the simultane-
ous loss of activating and repressing 
modifications and thus possible mutual 
suppression in vivo.
The single-cell approach used by 
Loewer and colleagues supports this 
latter hypothesis. They find that only 
cells experiencing true DNA mutagen-
esis possess acetylated p53 (i.e., the 
activated form of p53) and induce the 
transcription of p21. The application of 
deacetylase inhibitors during the normal 
cell cycle boosted the levels of acety-
lated p53 and increased expression of 
p21. Moreover, reducing the expression 
of a specific methyltransferase (SET8) 
stimulated the induction of p21 dur-
ing the normal cell cycle. These results 
indicate that repressive methylations on 
p53 keep it in check as it pulses during 
cell division; when actual DNA damage 
occurs, acetylation replaces the meth-
ylation to trigger p53 transcriptional 
activity.
Although this new study provides an 
elegant framework for understanding 
how the balance between methylation 
and acetylation of p53 may regulate 
its activity, many questions emerge 
from these results. For example, does 
methylation of lysine residues in the 
DNA binding domain of p53 (at K120 
and K164; Figure 1) also block acety-
lation and activation of p53 (Vousden 
and Prives, 2009)? In addition, there is 
evidence that deacetylases and dem-
ethylases also regulate p53 (Kruse and 
Gu 2009; Huang et al., 2007), and it is 
important to understand how these dif-
ferent classes of enzymes target p53, 
especially in terms of their role in cancer 
and tumorigenesis.
Further, it will be interesting to learn 
how ubiquitination at these same resi-
dues is integrated into the scheme that 
regulates p53. One reasonable overall 
scenario is that methylation represses 
p53 until irreconcilable breaks in the DNA 
occur outside of the normal cell cycle. 
Then activation of p53 occurs by a series 
of steps: acetylation blocks the repressive 
methylation, leading to an increase in the 
p53 protein and eventually to cell-cycle 
arrest (Figure 1). When the cell “wants” 
to resume growth, ubiquitination of these 
same lysines may attenuate this loop by 
stimulating degradation of p53.
Finally, placing the results of this study 
into the context of p53 research over 
the last decade also begs the question, 
“why is regulation of p53 so complex”? 
Is it because p53 is of profound impor-
tance to normal cell physiology, neces-
sitating intricate regulation that involves 
at least three alternative forms of post-
translational modifications on lysine? 
Or, is p53 simply studied more inten-
sively than other transcription factors, 
and thus more is known about its regu-
Figure 1. Posttranslational Modifications Regulate p53 Activity
The tumor suppressor p53 is a modular protein that contains (from the amino to the carboxyl terminus) two 
tandem activation domains (green), a DNA binding domain (tan), and an oligomerization domain surrounded 
by regulatory domains (red). Levels of p53 increase transiently during the normal cell cycle (Loewer et al., 
2010). However, the activity of p53 during these bursts is kept in check by methylation (red hexagons) of 
lysine residues (K370, K373, and K382) in the carboxyl terminus region. In contrast, dimethylation of K370 
and monomethylation of K372 activate p53 (Huang and Berger, 2008). In response to DNA damage, se-
quential regulatory steps occur. The p53 protein is phosphorylated (not shown) and acetylated at multiple 
sites (K120, K164, K320, K370, and K382). The level of p53 increases in the cell, triggering factors that 
repair the DNA and arrest the cell cycle. For cell division to resume, the stress response mediated by p53 
needs to be attenuated by deacetylation (not shown) and ubiquitin-mediated degradation of p53.18 Cell 142, July 9, 2010 ©2010 Elsevier Inc.
lation? This is a fascinating question, 
especially given that hundreds of non-
histone proteins are acetylated. More-
over, in the coming decade, researchers 
will probably identify an equal number 
of proteins that are methylated. Will 
opposing modifications on lysines be a 
general theme for regulating these fac-
tors, too? Only time and hard work will 
provide the answer.
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Transport vesicles ferry cargo from one 
cellular compartment to another. Coat 
proteins drive the formation of these 
vesicles by polymerizing onto the sur-
face of cellular membranes (Bonifacino 
and Glick, 2004). Because of the cen-
tral role these coats play in intracellular 
trafficking in all eukaryotes, their struc-
tures and their mechanisms of assem-
bly and disassembly have interested 
cell biologists for decades. Interest-
ingly, different coats are implicated in 
budding from different compartments 
(Figure 1A). For instance, endocytic 
vesicles coated with clathrin form at the 
plasma membrane, whereas vesicles 
coated with COPII complexes form at 
exit sites of the endoplasmic reticulum 
(ER). The third archetypal coat is COPI. 
ARF family G proteins recruit COPI 
to the membrane of the Golgi appa-
ratus, which serves as the source of 
COPI-coated vesicles. Detailed mod-
els of clathrin and COPII coats have 
been built by combining X-ray crystal 
structures of coat subcomplexes with 
cryo-electron microscopy (cryo-EM) 
analyses of coat lattices assembled 
in vitro (Fath et al., 2007; Fotin et al., 
2004; Stagg et al., 2006, 2008). In this 
issue of Cell, Lee and Goldberg (2010) 
present X-ray crystal structures of 
COPI components, making it possible 
to begin comparing the architectures 
of all three vesicle coats.
Vesicle coats have two layers: an 
inner “adaptor” layer that interacts with 
cargo and G proteins and an outer layer 
called a “cage.” For clathrin and COPII 
coats, these layers form sequentially, 
with adaptor protein complexes binding 
to the membrane first and then recruit-
ing cage components. In contrast, for 
COPI coats, both layers are recruited 
together as a single complex called 
“coatomer,” which contains seven sub-
units (Hara-Kuge et al., 1994; Waters 
et al., 1991). Four coatomer subunits, 
β, δ, γ, and ζ, resemble the subunits of 
the clathrin adaptor complex. To glean 
new insights into the architectural prin-
ciples of the COPI coat, Lee and Gold-
berg (2010) turned their attention to the 
remaining three subunits, α, β′, and ε, 
which together form the outer cage 
layer.
The vesicle cage imparts geometric 
order to the coat (Figure 1). For exam-
ple, cryo-electron tomography studies 
of clathrin-coated vesicles revealed 
various lattices drawn from the “soccer 
ball” family (Cheng et al., 2007). The 
assembly unit of the clathrin cage is the 
triskelion, with three elongated clathrin 
heavy chains joined at a central hub 
(Figures 1B and 1C). Cryo-EM studies 
of clathrin cages assembled in vitro 
revealed, at subnanometer resolution, 
how leg segments intertwine to form 
each edge of the lattice (Fotin et al., 
2004). The central hub of the triskelion 
resides at a vertex where three lattice 
edges intersect; indeed, the trimeric 
nature of the assembly unit guarantees 
that all the vertices in a clathrin cage 
are formed by the intersection of three 
edges (Figure 1C).
The structure of the COPII cage is 
remarkably different (Fath et al., 2007; 
Stagg et al., 2006, 2008). First, the 
assembly unit is not a triskelion but 
rather a rod-shaped heterotetramer of 
two Sec13 and two Sec31 subunits. 
Each (Sec13/31)
2 assembly unit forms a 
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The assembly of COPI into a cage-like lattice sculpts membrane vesicles that transport cargo 
from the Golgi apparatus. Now, Lee and Goldberg (2010) present X-ray crystal structures of COPI 
suggesting that these coats combine selected features of two other archetypal coats, clathrin and 
COPII.
